Layoff
Dec 2023Reportedly reduced workforce by about 60% (34 employees) and refocused resources on lead candidate AB248.
SourceCompany research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Asher Bio (Asher Biotherapeutics) is a clinical-stage, privately held biotechnology company founded in 2019 that develops cis-targeted immunotherapies designed to selectively activate specific immune cells and reduce off-target toxicity. Its lead product is etakafusp alfa (AB248), a CD8-targeted IL-2 immunotherapy in Phase 1 oncology studies; the broader pipeline includes AB821 and other cis-targeted cytokine programs.
Primary product
Etakafusp alfa (AB248), a CD8-targeted IL-2 immunotherapy
Founded
2019
Headquarters
650 Gateway Blvd. Suite 100, South San Francisco, CA 94080, USA
Team size
11-50
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
Open Positions
0 jobs at Asher Bio
No open positions
Check back later for new openings